Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Halozyme Therapeutics, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Halozyme Therapeutics amended its Bylaws on April 22, 2026 to allow shareholder removal of directors at any time by majority vote and clarified that shareholder actions require actual meetings. These governance changes enhance board flexibility and shareholder rights.
Key Takeaways
Section 2.5 amended to permit director removal at any time with or without cause by majority shareholder vote, increasing shareholder control
Section 1.12 clarified that shareholder actions cannot occur without an actual meeting, aligning with Certificate of Incorporation provisions
2 more takeaways